Alaproclate API Manufacturers
compare suppliers & get competitive offers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Looking for Alaproclate API 60719-82-6?
- Description:
- Here you will find a list of producers, manufacturers and distributors of Alaproclate. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Alaproclate
- Synonyms:
- Cas Number:
- 60719-82-6
- DrugBank number:
- DB13233
- Unique Ingredient Identifier:
- C4R42570ZO
General Description:
Alaproclate, identified by CAS number 60719-82-6, is a notable compound with significant therapeutic applications. Alaproclate was developed as one of the first selective serotonin reuptake inhibitor (SSRI) antidepressants by Astra AB (now AstraZeneca) in the 1970s. Development was discontinued due to concerns over hepatotoxicity observed in animal studies. Alaproclate has also been found to act as a non-competitive NMDA receptor antagonist although without discriminative stimulus properties similar to phencyclidine.
Classification:
Alaproclate belongs to the class of organic compounds known as alpha amino acid esters. These are ester derivatives of alpha amino acids, classified under the direct parent group Alpha amino acid esters. This compound is a part of the Organic compounds, falling under the Organic acids and derivatives superclass, and categorized within the Carboxylic acids and derivatives class, specifically within the Amino acids, peptides, and analogues subclass.
Categories:
Alaproclate is categorized under the following therapeutic classes: Amino Acids, Amino Acids, Peptides, and Proteins, Antidepressive Agents, Central Nervous System Agents, Central Nervous System Depressants, Hypoglycemia-Associated Agents, Membrane Transport Modulators, Nervous System, Neurotransmitter Agents, Neurotransmitter Uptake Inhibitors, Psychoanaleptics, Psychotropic Drugs, Selective Serotonin Reuptake Inhibitors, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin Agents, Serotonin Modulators. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.
Alaproclate is a type of Central Nervous System Agents
Central Nervous System (CNS) Agents are a crucial category of pharmaceutical Active Pharmaceutical Ingredients (APIs) that specifically target the central nervous system. The CNS encompasses the brain and spinal cord, playing a vital role in regulating and controlling various bodily functions, including cognition, movement, emotions, and sensory perception. These agents are designed to interact with specific receptors, enzymes, or ion channels within the CNS to modulate neural activity and restore normal functioning.
CNS agents comprise a diverse range of pharmaceutical APIs, including analgesics, anesthetics, antipsychotics, sedatives, hypnotics, anti-epileptics, and antidepressants. Each subcategory addresses distinct neurological disorders and conditions. For instance, analgesics alleviate pain by targeting receptors in the brain and spinal cord, while antipsychotics are employed to manage psychosis symptoms in mental illnesses such as schizophrenia.
The development of CNS agents involves rigorous research, molecular modeling, and extensive clinical trials to ensure safety, efficacy, and specific target engagement. Pharmaceutical companies invest significant resources in identifying novel drug targets, synthesizing new compounds, and optimizing their pharmacological properties. These agents undergo rigorous regulatory evaluations and must adhere to stringent quality standards and guidelines.
Given the prevalence of CNS disorders globally, the market demand for effective CNS agents is substantial. The development of innovative CNS APIs not only improves patient outcomes but also provides valuable commercial opportunities for pharmaceutical companies. Continued advancements in CNS agent research and development hold the promise of groundbreaking therapies that can improve the quality of life for individuals affected by neurological conditions.
